Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Luye Pharma Group ( (HK:2186) ) has provided an announcement.
Luye Pharma Group Ltd. has commenced a Phase II clinical trial for its new drug LY03015 in China, designed to treat tardive dyskinesia and Huntington’s disease. This drug, a VMAT2 inhibitor and Sigma-1 receptor agonist, offers potential superior efficacy and safety over current treatments, addressing significant market demand in the CNS drug space, and could enhance the company’s standing in the global pharmaceutical market.
More about Luye Pharma Group
Luye Pharma Group Ltd. operates in the pharmaceutical industry, focusing on the development of innovative drugs, particularly in the central nervous system (CNS) therapeutic area. The group’s portfolio includes internationally competitive products such as extended-release injectable suspensions and other CNS-related drugs, strengthening its position as a leader among Chinese pharmaceutical companies.
YTD Price Performance: -3.70%
Average Trading Volume: 1,000
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $968.1M
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.
